Daphnetin Ameliorates Neuropathic Pain via Regulation of Microglial Responses and Glycerophospholipid Metabolism in the Spinal Cord

This study investigates how daphnetin (DAP), a natural compound, can alleviate neuropathic pain (NP) in rats. The research focuses on the role of microglia, which are immune cells in the spinal cord, and their impact on pain sensation. The experiments showed that DAP treatment reduced pain sensitivity in rats with nerve injury. It also decreased the activation of microglia and the levels of inflammatory substances in the spinal cord. Furthermore, DAP was found to influence glycerophospholipid metabolism, a process involving fats in the spinal cord, which is believed to contribute to pain relief. This suggests that DAP could be a potential treatment for neuropathic pain by targeting microglia and fat metabolism in the spinal cord.

• 1
  DAP treatment ameliorated the mechanical withdrawal threshold (MWT) and thermal withdrawal threshold (TWT) in CCI rats, indicating reduced pain sensitivity.
• 2
  DAP inhibited the expression of IL-1β, IL-6, and TNF-α in the spinal cords of CCI rats, suggesting an anti-inflammatory effect.
• 3
  Proteomics and metabolomics results indicated that DAP ameliorated the imbalance of glycerophospholipid metabolism in the spinal cords of CCI rats.